Freda Lewis-Hall
About Freda Lewis-Hall
Freda Lewis-Hall, MD, is a psychiatrist and biopharmaceutical executive. She earned her undergraduate degree at Johns Hopkins University and her medical degree at Howard University College of Medicine. Before industry, she was vice chairperson and associate professor of psychiatry at Howard University College of Medicine and advised the National Institute of Mental Health.
She held senior roles at Eli Lilly, Pharmacia, Bristol-Myers Squibb and Vertex, where she was chief medical officer and executive vice president of medicines development from 2008. She joined Pfizer in 2009 as Chief Medical Officer. She later became chief patient officer and retired from Pfizer in 2020.
She served on the board of governors of the Patient-Centered Outcomes Research Institute from 2010 to 2020. Her public board roles include SpringWorks Therapeutics, 1Life Healthcare, Tenet Healthcare and Pyxis Oncology. MarketScreener lists her as an independent director at Cybin starting in 2026.
Public sources describe her as a venture partner at Catalio Capital, a life sciences investor that backs seed, early and later stage companies. NFX Signal lists her investing position there. It shows past investments tagged as seed and Series A in pharmaceuticals, biotech, digital health, health IT and consumer health. We did not find a public list of her individual angel investments with years.
Her AI deal on the Lounge deals desk is Cheiron. In July 2026, Cheiron announced an $8M seed round led by Menlo Ventures. Cheiron is a Los Altos, California company building an AI-native operating system for drug development programs. Press coverage lists her among the strategic backers, with Robert Langer, Josh Meier, Laxman Narasimhan and John Giannandrea.
Her public investing activity is in life sciences and healthcare: biotech, pharmaceuticals, digital health and health IT, mostly at seed and Series A. The Cheiron round shows interest in AI applied to drug development. NFX Signal lists an investment range of $100K to $5.0M and a sweet spot of $1.5M. That profile is for her Catalio role, and she has not stated a personal angel check size publicly. We found no public statement from her on what she looks for in pitches.
- Cheiron: AI-native operating system for drug development programs; she was a strategic backer of its $8M seed round announced in July 2026.
- thepharmaletter.com/pharma-news/cheiron-lands-8-million-seed-to-turn-t
- hitconsultant.net/2026/07/22/cheiron-raises-8m-seed-menlo-ventures-dru
- pcori.org/people/freda-lewis-hall-md
- thehistorymakers.org/biography/dr-freda-lewis-hall
- pfizer.com/news/press-release/press-release-detail/dr_freda_lewis_hall
- investors.vrtx.com/news-releases/news-release-details/vertex-pharmaceu
- signal.nfx.com/investors/freda-lewis-hall
- marketscreener.com/insider/FREDA-LEWIS-HALL-A0215K
Investing activity
Freda Lewis-Hall appears in 1 AI deal tracked by the Lounge deals desk. The rounds are mostly Seed, with a median round size of $8M. The most recent is Cheiron (Seed, $8M, Jul 2026).
Freda Lewis-Hall most often invests alongside Menlo Ventures, Robert Langer, Josh Meier and Laxman Narasimhan, and the companies they back on Lounge are mostly in AI.
Deals
Frequently asked questions about Freda Lewis-Hall
Who is Freda Lewis-Hall?
She is a physician and former Pfizer Chief Medical Officer and chief patient officer. She is now a venture partner at Catalio Capital and sits on company boards.
Has Freda Lewis-Hall invested in AI startups?
Yes. She was a named backer of Cheiron's $8M seed round, led by Menlo Ventures and announced in July 2026. Cheiron builds AI software for drug development programs.
What stage does Freda Lewis-Hall invest in?
NFX Signal shows her investments at seed and Series A. Her Catalio Capital profile covers life sciences and healthcare.
What is Freda Lewis-Hall's check size?
She has not stated a personal check size publicly. NFX Signal lists a $100K to $5.0M range with a $1.5M sweet spot for her investing profile at Catalio.
What sectors does Freda Lewis-Hall back?
Her public investments are in biotech, pharmaceuticals, digital health, health IT and consumer health, plus AI for drug development through Cheiron.
How can AI founders pitch Freda Lewis-Hall?
She has no public pitch process. Her LinkedIn profile is the public channel. Founders in AI for drug development and clinical operations are the closest fit with her track record.
Is Freda Lewis-Hall an angel investor?
Yes. Freda Lewis-Hall invests personally as an angel.
What AI companies has Freda Lewis-Hall invested in?
Freda Lewis-Hall's AI investments include Cheiron. The 1 round on Lounge are listed on this page with amounts, dates and co-investors.
What stage does Freda Lewis-Hall invest at?
In the rounds tracked on Lounge, Freda Lewis-Hall has invested at Seed, with a median round of $8M.
Who does Freda Lewis-Hall co-invest with?
Freda Lewis-Hall's most frequent co-investors on Lounge are Menlo Ventures (1 deal), Robert Langer (1 deal), Josh Meier (1 deal), Laxman Narasimhan (1 deal) and John Giannandrea (1 deal).